Calcific and Degenerative Heart Valve Disease

Cellular and Molecular Pathobiology of Cardiovascular Disease

Volumn , Issue , 2014, Pages 161-180

  Aikawa, Elena ^a   Schoen, Frederick J ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Calcific aortic valve disease; Degenerative mitral valve disease; Disease models; Heart valve biology; Mechanisms; Valvular endothelial cells; Valvular interstitial cells

Indexed keywords

EID: 84902748473     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-405206-2.00009-0     Document Type: Chapter

References (125)

1. Roger V.L., Go A.S., Lloyd-Jones D.M., Benjamin E.J., Berry J.D., Borden W.B., et al. Heart disease and stroke statistics-2012 update: A report from the American Heart Association. Circulation 2012, 125. e2-e220.
2. Iung B., Vahanian A. Epidemiology of valvular heart disease in the adult. Nat Rev Cardiol 2011, 8:162-172.
3. Schoen F.J. Mechanisms of function and disease of natural and replacement heart valves. Annu Rev Pathol 2012, 7:161-183.
4. Rabkin E., Aikawa M., Stone J.R., Fukumoto Y., Libby P., Schoen F.J. Activated interstitial myofibroblasts express catabolic enzymes and mediate matrix remodeling in myxomatous heart valves. Circulation 2001, 104:2525-2532.
5. Schoen F.J. Evolving concepts of cardiac valve dynamics: The continuum of development, functional structure, pathobiology, and tissue engineering. Circulation 2008, 118:1864-1880.
6. Rabkin-Aikawa E., Aikawa M., Farber M., Kratz J.R., Garcia-Cardena G., Kouchoukos N.T., et al. Clinical pulmonary autograft valves: Pathologic evidence of adaptive remodeling in the aortic site. J Thorac Cardiovasc Surg 2004, 128:552-561.
7. Bashey R.I., Torii S., Angrist A. Age-related collagen and elastin content of human heart valves. J Gerontol 1967, 22:203-208.
8. Sacks M.S., David Merryman W., Schmidt D.E. On the biomechanics of heart valve function. J Biomech 2009, 42:1804-1824.
9. Kunzelman K.S., Cochran R.P., Murphree S.S., Ring W.S., Verrier E.D., Eberhart R.C. Differential collagen distribution in the mitral valve and its influence on biomechanical behaviour. J Heart Valve Dis 1993, 2:236-244.
10. Grashow J.S., Yoganathan A.P., Sacks M.S. Biaixal stress-stretch behavior of the mitral valve anterior leaflet at physiologic strain rates. Ann Biomed Eng 2006, 34:315-325.
11. Bischoff J., Aikawa E. Progenitor cells confer plasticity to cardiac valve endothelium. J Cardiovasc Transl Res 2011, 4:710-719.
12. Butcher J.T., Penrod A.M., Garcia A.J., Nerem R.M. Unique morphology and focal adhesion development of valvular endothelial cells in static and fluid flow environments. Arterioscler Thromb Vasc Biol 2004, 24:1429-1434.
13. Simmons C.A., Grant G.R., Manduchi E., Davies P.F. Spatial heterogeneity of endothelial phenotypes correlates with side-specific vulnerability to calcification in normal porcine aortic valves. Circ Res 2005, 96:792-799.
14. Weinberg E.J., Mack P.J., Schoen F.J., Garcia-Cardena G., Kaazempur Mofrad M.R. Hemodynamic environments from opposing sides of human aortic valve leaflets evoke distinct endothelial phenotypes in vitro. Cardiovasc Eng 2010, 10:5-11.
15. Markwald R.R., Norris R.A., Moreno-Rodriguez R., Levine R.A. Developmental basis of adult cardiovascular diseases: Valvular heart diseases. Ann N Y Acad Sci 2010, 1188:177-183.
16. Wylie-Sears J., Aikawa E., Levine R.A., Yang J.H., Bischoff J. Mitral valve endothelial cells with osteogenic differentiation potential. Arterioscler Thromb Vasc Biol 2011, 31:598-607.
17. Chakraborty S., Cheek J., Sakthivel B., Aronow B.J., Yutzey K.E. Shared gene expression profiles in developing heart valves and osteoblast progenitor cells. Physiol Genomics 2008, 35:75-85.
18. Aikawa E., Whittaker P., Farber M., Mendelson K., Padera R.F., Aikawa M., et al. Human semilunar cardiac valve remodeling by activated cells from fetus to adult: Implications for postnatal adaptation, pathology, and tissue engineering. Circulation 2006, 113:1344-1352.
19. Rabkin-Aikawa E., Farber M., Aikawa M., Schoen F.J. Dynamic and reversible changes of interstitial cell phenotype during remodeling of cardiac valves. J Heart Valve Dis 2004, 13:841-847.
20. Aikawa E., Aikawa M., Libby P., Figueiredo J.L., Rusanescu G., Iwamoto Y., et al. Arterial and aortic valve calcification abolished by elastolytic cathepsin S Deficiency in Chronic Renal Disease. Circulation 2009, 119:1785-1794.
21. Liu A.C., Joag V.R., Gotlieb A.I. The emerging role of valve interstitial cell phenotypes in regulating heart valve pathobiology. Am J Pathol 2007, 171:1407-1418.
22. Combs M.D., Yutzey K.E. Heart valve development: Regulatory networks in development and disease. Circ Res 2009, 105:408-421.
23. Tao G., Levay A.K., Gridley T., Lincoln J. MMP14 is a direct target of snai1 during endothelial to mesenchymal transformation and endocardial cushion development. Dev Biol 2011, 359:209-221.
24. Lincoln J., Lange A.W., Yutzey K.E. Hearts and bones: Shared regulatory mechanisms in heart valve, cartilage, tendon, and bone development. Dev Biol 2006, 294:292-302.
25. Alfieri C.M., Cheek J., Chakraborty S., Yutzey K.E. Wnt signaling in heart valve development and osteogenic gene induction. Dev Biol 2010, 338:127-135.
26. Norris R.A., Moreno-Rodriguez R.A., Sugi Y., Hoffman S., Amos J., Hart M.M., et al. Periostin regulates atrioventricular valve maturation. Dev Biol 2008, 316:200-213.
27. Hinton R.B., Adelman-Brown J., Witt S., Krishnamurthy V.K., Osinska H., Sakthivel B., et al. Elastin haploinsufficiency results in progressive aortic valve malformation and latent valve disease in a mouse model. Circ Res 2010, 107:549-557.
28. Aikawa E., Nahrendorf M., Sosnovik D., Lok V.M., Jaffer F.A., Aikawa M., et al. Multimodality molecular imaging identifies proteolytic and osteogenic activities in early aortic valve disease. Circulation 2007, 115:377-386.
29. Dal-Bianco J.P., Aikawa E., Bischoff J., Guerrero J.L., Handschumacher M.D., Sullivan S., et al. Active adaptation of the tethered mitral valve: Insights into a compensatory mechanism for functional mitral regurgitation. Circulation 2009, 120:334-342.
30. Otto C.M., Kuusisto J., Reichenbach D.D., Gown A.M., O'Brien K.D. Characterization of the early lesion of `degenerative' valvular aortic stenosis. Histological and immunohistochemical studies. Circulation 1994, 90:844-853.
31. Mohler E.R., Gannon F., Reynolds C., Zimmerman R., Keane M.G., Kaplan F.S. Bone formation and inflammation in cardiac valves. Circulation 2001, 103:1522-1528.
32. Pomerance A. Ageing changes in human heart valves. Br Heart J 1967, 29:222-231.
33. Stewart B.F., Siscovick D., Lind B.K., Gardin J.M., Gottdiener J.S., Smith V.E., et al. Clinical factors associated with calcific aortic valve disease. Cardiovascular Health Study. J Am Coll Cardiol 1997, 29:630-634.
34. Otto C.M., Lind B.K., Kitzman D.W., Gersh B.J., Siscovick D.S. Association of aortic-valve sclerosis with cardiovascular mortality and morbidity in the elderly. N Engl J Med 1999, 341:142-147.
35. Rajamannan N.M., Evans F.J., Aikawa E., Grande-Allen K.J., Demer L.L., Heistad D.D., et al. Calcific aortic valve disease: Not simply a degenerative process: A review and agenda for research from the National Heart, Lung and Blood Institute Aortic Stenosis Working Group. Executive summary: Calcific aortic valve disease-2011 update. Circulation 2011, 124:1783-1791.
36. Ortlepp J.R., Hoffmann R., Ohme F., Lauscher J., Bleckmann F., Hanrath P. The vitamin D receptor genotype predisposes to the development of calcific aortic valve stenosis. Heart 2001, 85:635-638.
37. Nordstrom P., Glader C.A., Dahlen G., Birgander L.S., Lorentzon R., Waldenstrom A., et al. Oestrogen receptor alpha gene polymorphism is related to aortic valve sclerosis in postmenopausal women. J Intern Med 2003, 254:140-146.
38. Novaro G.M., Sachar R., Pearce G.L., Sprecher D.L., Griffin B.P. Association between apolipoprotein E alleles and calcific valvular heart disease. Circulation 2003, 108:1804-1808.
39. Ortlepp J.R., Schmitz F., Mevissen V., Weiss S., Huster J., Dronskowski R., et al. The amount of calcium-deficient hexagonal hydroxyapatite in aortic valves is influenced by gender and associated with genetic polymorphisms in patients with severe calcific aortic stenosis. Eur Heart J 2004, 25:514-522.
40. Otto C.M., Pearlman A.S., Gardner C.L. Hemodynamic progression of aortic stenosis in adults assessed by doppler echocardiography. J Am Coll Cardiol 1989, 13:545-550.
41. Cosmi J.E., Kort S., Tunick P.A., Rosenzweig B.P., Freedberg R.S., Katz E.S., et al. The risk of the development of aortic stenosis in patients with "benign" aortic valve thickening. Arch Intern Med 2002, 162:2345-2347.
42. Dweck M.R., Jones C., Joshi N.V., Fletcher A.M., Richardson H., White A., et al. Assessment of valvular calcification and inflammation by positron emission tomography in patients with aortic stenosis. Circulation 2012, 125:76-86.
43. Aikawa E., Otto C.M. Look more closely at the valve: Imaging calcific aortic valve disease. Circulation 2012, 125:9-11.
44. Huntington K., Hunter A.G., Chan K.L. A prospective study to assess the frequency of familial clustering of congenital bicuspid aortic valve. J Am Coll Cardiol 1997, 30:1809-1812.
45. Li C., Xu S., Gotlieb A.I. The progression of calcific aortic valve disease through injury, cell dysfunction, and disruptive biologic and physical force feedback loops. Cardiovasc Pathol 2013, 22:1-8.
46. Yip C.Y., Chen J.H., Zhao R., Simmons C.A. Calcification by valve interstitial cells is regulated by the stiffness of the extracellular matrix. Arterioscler Thromb Vasc Biol 2009, 29:936-942.
47. Jian B., Jones P.L., Li Q., Mohler E.R., Schoen F.J., Levy R.J. Matrix metalloproteinase-2 is associated with tenascin-C in calcific aortic stenosis. Am J Pathol 2001, 159:321-327.
48. Rajamannan N.M., Subramaniam M., Rickard D., Stock S.R., Donovan J., Springett M., et al. Human aortic valve calcification is associated with an osteoblast phenotype. Circulation 2003, 107:2181-2184.
49. Rodriguez K.J., Masters K.S. Regulation of valvular interstitial cell calcification by components of the extracellular matrix. J Biomed Mater Res A 2009, 90:1043-1053.
50. Chen J.H., Yip C.Y., Sone E.D., Simmons C.A. Identification and characterization of aortic valve mesenchymal progenitor cells with robust osteogenic calcification potential. Am J Pathol 2009, 174:1109-1119.
51. Kapustin A.N., Davies J.D., Reynolds J.L., McNair R., Jones G.T., Sidibe A., et al. Calcium regulates key components of vascular smooth muscle cell-derived matrix vesicles to enhance mineralization. Circ Res 2011, 109:e1-12.
52. New S.E.P., Goettsch C., Aikawa M., Marchini J.F., Shibasaki M., Yabusaki K., et al. Macrophage-derived matrix vesicles: An alternative novel mechanism for microcalcification in atherosclerotic plaques. Circulation Research 2013, 113:72-77.
53. New S.E.P., Aikawa E. The role of extracellular vesicles in de novo mineralization: An additional novel mechanism of cardiovascular calcification. ATVB 2013, 33:1753-1758.
54. Kim K.M. Calcification of matrix vesicles in human aortic valve and aortic media. Fed Proc 1976, 35:156-162.
55. Merryman W.D.S.F., Schoen F.J. Mechanisms of calcification in aortic valve disease: Role of mechanokinetics and mechanodynamics. Curr Cardiol Rep 2013, 15:355-1361.
56. Sucosky P., Balachandran K., Elhammali A., Jo H., Yoganathan A.P. Altered shear stress stimulates upregulation of endothelial VCAM-1 and ICAM-1 in a BMP-4 and TGF-beta1-dependent pathway. Arterioscler Thromb Vasc Biol 2009, 29:254-260.
57. Mirzaie M., Schultz M., Schwartz P., Coulibaly M., Schondube F. Evidence of woven bone formation in heart valve disease. Ann Thorac Cardiovasc Surg 2003, 9:163-169.
58. Balachandran K., Sucosky P., Jo H., Yoganathan A.P. Elevated cyclic stretch induces aortic valve calcification in a bone morphogenic protein-dependent manner. Am J Pathol 2010, 177:49-57.
59. Muller A.M., Cronen C., Kupferwasser L.I., Oelert H., Muller K.M., Kirkpatrick C.J. Expression of endothelial cell adhesion molecules on heart valves: Up-regulation in degeneration as well as acute endocarditis. J Pathol 2000, 191:54-60.
60. El-Hamamsy I., Balachandran K., Yacoub M.H., Stevens L.M., Sarathchandra P., Taylor P.M., et al. Endothelium-dependent regulation of the mechanical properties of aortic valve cusps. J Am Coll Cardiol 2009, 53:1448-1455.
61. Galante A., Pietroiusti A., Vellini M., Piccolo P., Possati G., De Bonis M., et al. C-reactive protein is increased in patients with degenerative aortic valvular stenosis. J Am Coll Cardiol 2001, 38:1078-1082.
62. Rajamannan N.M., Subramaniam M., Caira F., Stock S.R., Spelsberg T.C. Atorvastatin inhibits hypercholesterolemia-induced calcification in the aortic valves via the LRP5 receptor pathway. Circulation 2005, 112:I229-I234.
63. Drolet M.C., Roussel E., Deshaies Y., Couet J., Arsenault M. A high fat/high carbohydrate diet induces aortic valve disease in C57B1/6J mice. J Am Coll Cardiol 2006, 47:850-855.
64. Tanaka K., Sata M., Fukuda D., Suematsu Y., Motomura N., Takamoto S., et al. Age-associated aortic stenosis in apolipoprotein E-deficient mice. J Am Coll Cardiol 2005, 46:134-141.
65. Weiss R.M., Ohashi M., Miller J.D., Young S.G., Heistad D.D. Calcific aortic valve stenosis in old hypercholesterolemic mice. Circulation 2006, 114:2065-2069.
66. New S.E., Aikawa E. Molecular imaging insights into early inflammatory stages of arterial and aortic valve calcification. Circ Res 2011, 108:1381-1391.
67. Aikawa E., Nahrendorf M., Figueiredo J.L., Swirski F.K., Shtatland T., Kohler R.H., et al. Osteogenesis associates with inflammation in early-stage atherosclerosis evaluated by molecular imaging in vivo. Circulation 2007, 116:2841-2850.
68. Hjortnaes J., Butcher J., Figueiredo J.L., Riccio M., Kohler R.H., Kozloff K.M., et al. Arterial and aortic valve calcification inversely correlates with osteoporotic bone remodelling: A role for inflammation. Eur Heart J 2010, 31:1975-1984.
69. Miller J.D., Chu Y., Brooks R.M., Richenbacher W.E., Pena-Silva R., Heistad D.D. Dysregulation of antioxidant mechanisms contributes to increased oxidative stress in calcific aortic valvular stenosis in humans. J Am Coll Cardiol 2008, 52:843-850.
70. Liberman M., Bassi E., Martinatti M.K., Lario F.C., Wosniak J., Pomerantzeff P.M., et al. Oxidant generation predominates around calcifying foci and enhances progression of aortic valve calcification. Arterioscler Thromb Vasc Biol 2008, 28:463-470.
71. Cote C., Pibarot P., Despres J.P., Mohty D., Cartier A., Arsenault B.J., et al. Association between circulating oxidised low-density lipoprotein and fibrocalcific remodelling of the aortic valve in aortic stenosis. Heart 2008, 94:1175-1180.
72. Thanassoulis G., Campbell C.Y., Owens D.S., Smith J.G., Smith A.V., Peloso G.M., et al. Genetic associations with valvular calcification and aortic stenosis. N Engl J Med 2013, 368:503-512.
73. Long F. Building strong bones: Molecular regulation of the osteoblast lineage. Nat Rev Mol Cell Biol 2012, 13:27-38.
74. Caira F.C., Stock S.R., Gleason T.G., McGee E.C., Huang J., Bonow R.O., et al. Human degenerative valve disease is associated with up-regulation of low-density lipoprotein receptor-related protein 5 receptor-mediated bone formation. J Am Coll Cardiol 2006, 47:1707-1712.
75. Miller J.D., Weiss R.M., Serrano K.M., Castaneda L.E., Brooks R.M., Zimmerman K., et al. Evidence for active regulation of pro-osteogenic signaling in advanced aortic valve disease. Arterioscler Thromb Vasc Biol 2010, 30:2482-2486.
76. Osman L., Yacoub M.H., Latif N., Amrani M., Chester A.H. Role of human valve interstitial cells in valve calcification and their response to atorvastatin. Circulation 2006, 114:I547-I552.
77. Miller J.D., Weiss R.M., Serrano K.M., Brooks R.M., Berry C.J., Zimmerman K., et al. Lowering plasma cholesterol levels halts progression of aortic valve disease in mice. Circulation 2009, 119:2693-2701.
78. Galvin K.M., Donovan M.J., Lynch C.A., Meyer R.I., Paul R.J., Lorenz J.N., et al. A role for smad6 in development and homeostasis of the cardiovascular system. Nat Genet 2000, 24:171-174.
79. Kaden J.J., Bickelhaupt S., Grobholz R., Vahl C.F., Hagl S., Brueckmann M., et al. Expression of bone sialoprotein and bone morphogenetic protein-2 in calcific aortic stenosis. J Heart Valve Dis 2004, 13:560-566.
80. Simonet W.S., Lacey D.L., Dunstan C.R., Kelley M., Chang M.S., Luthy R., et al. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cellule 1997, 89:309-319.
81. Kaden J.J., Dempfle C.E., Grobholz R., Fischer C.S., Vocke D.C., Kilic R., et al. Inflammatory regulation of extracellular matrix remodeling in calcific aortic valve stenosis. Cardiovasc Pathol 2005, 14:80-87.
82. Kaden J.J., Kilic R., Sarikoc A., Hagl S., Lang S., Hoffmann U., et al. Tumor necrosis factor alpha promotes an osteoblast-like phenotype in human aortic valve myofibroblasts: A potential regulatory mechanism of valvular calcification. Int J Mol Med 2005, 16:869-872.
83. Nanes M.S. Tumor necrosis factor-alpha: Molecular and cellular mechanisms in skeletal pathology. Genewatch 2003, 321:1-15.
84. Miller J.D., Weiss R.M., Heistad D.D. Calcific aortic valve stenosis: Methods, models, and mechanisms. Circ Res 2011, 108:1392-1412.
85. Walker G.A., Masters K.S., Shah D.N., Anseth K.S., Leinwand L.A. Valvular myofibroblast activation by transforming growth factor-beta: Implications for pathological extracellular matrix remodeling in heart valve disease. Circ Res 2004, 95:253-260.
86. Proudfoot D., Skepper J.N., Hegyi L., Bennett M.R., Shanahan C.M., Weissberg P.L. Apoptosis regulates human vascular calcification in vitro: Evidence for initiation of vascular calcification by apoptotic bodies. Circ Res 2000, 87:1055-1062.
87. Mohler E.R., Chawla M.K., Chang A.W., Vyavahare N., Levy R.J., Graham L., et al. Identification and characterization of calcifying valve cells from human and canine aortic valves. J Heart Valve Dis 1999, 8:254-260.
88. O'Brien K.D., Shavelle D.M., Caulfield M.T., McDonald T.O., Olin-Lewis K., Otto C.M., et al. Association of angiotensin-converting enzyme with low-density lipoprotein in aortic valvular lesions and in human plasma. Circulation 2002, 106:2224-2230.
89. Arishiro K., Hoshiga M., Negoro N., Jin D., Takai S., Miyazaki M., et al. Angiotensin receptor-1 blocker inhibits atherosclerotic changes and endothelial disruption of the aortic valve in hypercholesterolemic rabbits. J Am Coll Cardiol 2007, 49:1482-1489.
90. Shavelle D.M., Takasu J., Budoff M.J., Mao S., Zhao X.Q., O'Brien K.D. HMG CoA reductase inhibitor (statin) and aortic valve calcium. Lancet 2002, 359:1125-1126.
91. Rosenhek R., Rader F., Loho N., Gabriel H., Heger M., Klaar U., et al. Statins but not angiotensin-converting enzyme inhibitors delay progression of aortic stenosis. Circulation 2004, 110:1291-1295.
92. Deregowski V., Gazzerro E., Priest L., Rydziel S., Canalis E. Notch 1 overexpression inhibits osteoblastogenesis by suppressing WNT/beta-catenin but not bone morphogenetic protein signaling. J Biol Chem 2006, 281:6203-6210.
93. Hilton M.J., Tu X., Wu X., Bai S., Zhao H., Kobayashi T., et al. Notch signaling maintains bone marrow mesenchymal progenitors by suppressing osteoblast differentiation. Nat Med 2008, 14:306-314.
94. Mead T.J., Yutzey K.E. Notch pathway regulation of chondrocyte differentiation and proliferation during appendicular and axial skeleton development. Proc Natl Acad Sci U S A 2009, 106:14420-14425.
95. Garg V., Muth A.N., Ransom J.F., Schluterman M.K., Barnes R., King I.N., et al. Mutations in NOTCH1 cause aortic valve disease. Nature 2005, 437:270-274.
96. Arrington C.B., Sower C.T., Chuckwuk N., Stevens J., Leppert M.F., Yetman A.T., et al. Absence of TGFBR1 and TGFBR2 mutations in patients with bicuspid aortic valve and aortic dilation. Am J Cardiol 2008, 102:629-631.
97. Nigam V., Srivastava D. Notch1 represses osteogenic pathways in aortic valve cells. J Mol Cell Cardiol 2009, 47:828-834.
98. Matsumoto Y., Adams V., Jacob S., Mangner N., Schuler G., Linke A. Regular exercise training prevents aortic valve disease in low-density lipoprotein-receptor-deficient mice. Circulation 2010, 121:759-767.
99. Cowell S.J., Newby D.E., Prescott R.J., Bloomfield P., Reid J., Northridge D.B., et al. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med 2005, 352:2389-2397.
100. Mohler E.R., Wang H., Medenilla E., Scott C. Effect of statin treatment on aortic valve and coronary artery calcification. J Heart Valve Dis 2007, 16:378-386.
101. Verma S., Szmitko P.E., Fedak P.W., Errett L., Latter D.A., David T.E. Can statin therapy alter the natural history of bicuspid aortic valves?. Am J Physiol Heart Circ Physiol 2005, 288:H2547-H2549.
102. Hayek E., Gring C.N., Griffin B.P. Mitral valve prolapse. Lancet 2005, 365:507-518.
103. Fornes P., Heudes D., Fuzellier J.F., Tixier D., Bruneval P., Carpentier A. Correlation between clinical and histologic patterns of degenerative mitral valve insufficiency: A histomorphometric study of 130 excised segments. Cardiovasc Pathol 1999, 8:81-92.
104. Barber J.E., Kasper F.K., Ratliff N.B., Cosgrove D.M., Griffin B.P., Vesely I. Mechanical properties of myxomatous mitral valves. J Thorac Cardiovasc Surg 2001, 122:955-962.
105. Barber J.E., Ratliff N.B., Cosgrove D.M., Griffin B.P., Vesely I. Myxomatous mitral valve chordae. I: Mechanical properties. J Heart Valve Dis 2001, 10:320-324.
106. Carpentier A., Chauvaud S., Fabiani J.N., Deloche A., Relland J., Lessana A., et al. Reconstructive surgery of mitral valve incompetence: Ten-year appraisal. J Thorac Cardiovasc Surg 1980, 79:338-348.
107. Anyanwu A.C., Adams D.H. Etiologic classification of degenerative mitral valve disease: Barlow's disease and fibroelastic deficiency. Semin Thorac Cardiovasc Surg 2007, 19:90-96.
108. Guy T.S., Hill A.C. Mitral valve prolapse. Annu Rev Med 2012, 63:277-292.
109. Grande-Allen K.J., Calabro A., Gupta V., Wight T.N., Hascall V.C., Vesely I. Glycosaminoglycans and proteoglycans in normal mitral valve leaflets and chordae: Association with regions of tensile and compressive loading. Glycobiology 2004, 14:621-633.
110. Flanagan T.C., Wilkins B., Black A., Jockenhoevel S., Smith T.J., Pandit A.S. A collagen-glycosaminoglycan co-culture model for heart valve tissue engineering applications. Biomaterials 2006, 27:2233-2246.
111. Flanagan T.C., Black A., O'Brien M., Smith T.J., Pandit A.S. Reference models for mitral valve tissue engineering based on valve cell phenotype and extracellular matrix analysis. Cells Tissues Organs 2006, 183:12-23.
112. Liu A.C., Gotlieb A.I. Transforming growth factor-beta regulates in vitro heart valve repair by activated valve interstitial cells. Am J Pathol 2008, 173:1275-1285.
113. Gotlieb A.I., Rosenthal A., Kazemian P. Fibroblast growth factor 2 regulation of mitral valve interstitial cell repair in vitro. J Thorac Cardiovasc Surg 2002, 124:591-597.
114. Gupta V., Werdenberg J.A., Lawrence B.D., Mendez J.S., Stephens E.H., Grande-Allen K.J. Reversible secretion of glycosaminoglycans and proteoglycans by cyclically stretched valvular cells in 3D culture. Ann Biomed Eng 2008, 36:1092-1103.
115. Nguyen T.C., Itoh A., Carlhall C.J., Bothe W., Timek T.A., Ennis D.B., et al. The effect of pure mitral regurgitation on mitral annular geometry and three-dimensional saddle shape. J Thorac Cardiovasc Surg 2008, 136:557-565.
116. Goetz W.A., Lim H.S., Pekar F., Saber H.A., Weber P.A., Lansac E., et al. Anterior mitral leaflet mobility is limited by the basal stay chords. Circulation 2003, 107:2969-2974.
117. Tamura K., Jones M., Yamada I., Ferrans V.J. Wound healing in the mitral valve. J Heart Valve Dis 2000, 9:53-63.
118. Ryan L.P., Jackson B.M., Parish L.M., Plappert T.J., St John-Sutton M.G., Gorman J.H., et al. Regional and global patterns of annular remodeling in ischemic mitral regurgitation. Ann Thorac Surg 2007, 84:553-559.
119. Stephens E.H., Timek T.A., Daughters G.T., Kuo J.J., Patton A.M., Baggett L.S., et al. Significant changes in mitral valve leaflet matrix composition and turnover with tachycardia-induced cardiomyopathy. Circulation 2009, 120:S112-S119.
120. Kunzelman K.S., Quick D.W., Cochran R.P. Altered collagen concentration in mitral valve leaflets: Biochemical and finite element analysis. Ann Thorac Surg 1998, 66:S198-S205.
121. Stephens E.H., Nguyen T.C., Itoh A., Ingels N.B., Miller D.C., Grande-Allen K.J. The effects of mitral regurgitation alone are sufficient for leaflet remodeling. Circulation 2008, 118:S243-S249.
122. Grammer J.B., Eichinger W.B., Bleiziffer S., Benz M.R., Lange R., Bauernschmitt R. Valvular chondromodulin-1 expression is downregulated in a rabbit model of infective endocarditis. J Heart Valve Dis 2007, 16:623-630. discussion 630.
123. Zeng Z., Nievelstein-Post P., Yin Y., Jan K.M., Frank J.S., Rumschitzki D.S. Macromolecular transport in heart valves. Iii. Experiment and theory for the size distribution of extracellular liposomes in hyperlipidemic rabbits. Am J Physiol Heart Circ Physiol 2007, 292:H2687-H2697.
124. Makkena B., Salti H., Subramaniam M., Thennapan S., Bonow R.H., Caira F., et al. Atorvastatin decreases cellular proliferation and bone matrix expression in the hypercholesterolemic mitral valve. J Am Coll Cardiol 2005, 45:631-633.
125. Ng C.M., Cheng A., Myers L.A., Martinez-Murillo F., Jie C., Bedja D., et al. TGF-beta-dependent pathogenesis of mitral valve prolapse in a mouse model of marfan syndrome. J Clin Invest 2004, 114:1586-1592.